Pricing & Sizes
Vials ship sealed and lyophilized. Free shipping on every order, no minimum. Every batch ships with its lab report. Reports come from third-party labs including Janoshik, Freedom Diagnostics and Chromate, most verifiable through the lab's own public portal. Ask and we will send the report for your batch.
Lab report on file. Current batch tested by Janoshik — HPLC. Verifiable through the lab's public portal; ask and we will send it.
Reconstitution — bacteriostatic water: 10mg vial reconstituted at 2mL gives 5mg/mL; Solution — 10mg in 4mL bacteriostatic saline = 2.5mg/mL. These are concentrations, calculated from vial content and diluent volume. They describe the solution, not a dose.
Email To OrderIn Plain English
Think of Semax as a signal telling your brain to build and protect more of its own wiring. Two natural brain chemicals — BDNF and NGF — act like fertiliser for brain cells: they help existing neurons survive stress and help new connections form. Semax raises production of both at once, which is why it has been studied for stroke recovery and for protecting memory as the brain ages.
What people use it for. Focus, mental stamina, cognitive recovery and mood. It is the closest thing in this category to a nootropic with a real clinical history, and it is most often paired with Selank to take the edge off.
What to know before you buy. Route is the thing that separates this compound from most others in the range: the published work is intranasal almost without exception, and the oral literature is effectively empty. Semax is the activating half of the Semax/Selank pairing, which is the distinction most of the research turns on.
What It's Studied For
| Research area | What that rests on |
|---|---|
| Focus and mental stamina | A controlled study in healthy fatigued adults reported 71% memory-test accuracy versus 41% in controls |
| Cognitive recovery | Used clinically in Russia since 1994 for stroke recovery and cognitive impairment |
| Brain resilience | Raises BDNF and NGF — two growth factors central to neuron survival and new connections |
| Mood research | Widely reported; mechanistically consistent with its dopaminergic activity |
The left column lists the research areas this compound is investigated in; the right column states what that rests on. These are published research findings, not proven outcomes or treatment claims, and nothing here is a recommendation. Sold for laboratory research use only.
At a Glance
- Class
- ACTH(4-7) analogue with a C-terminal Pro-Gly-Pro extension
- Mechanism
- Upregulates BDNF and NGF — brain-derived and nerve growth factors — in hippocampus, frontal cortex and retina
- Origin
- Institute of Molecular Genetics, Russian Academy of Sciences
- Regulatory (Russia)
- Approved prescription medication since 1994 for stroke recovery and cognitive impairment
- Regulatory (US)
- Not FDA-approved. PCAC recommended for 503A listing 24 July 2026; no FDA action taken
- Reviewed for
- Cerebral ischaemia, migraine, and trigeminal neuralgia
- Route
- Intranasal is the native route; oral bioavailability is essentially zero
- Format
- 10mg vial, or prepared solution in a 4mL bottle
Regulatory status
On 24 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-5-1 to recommend Semax (free base and acetate) for the Section 503A bulk drug substances list. That vote is advisory only. As of 17 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA’s own scientific reviewers had recommended against all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency’s decision is weaker here than normal. Several outlets have reported this as the FDA “clearing”, “approving” or “adding” these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.
Why Semax Stands Out
Most research peptides have never been used in a real patient population. Semax has, for over thirty years, within an established clinical pharmaceutical system. That is a meaningfully different evidence tier from a peptide backed only by mouse studies — though it is not equivalent to FDA-standard evidence, and FDA said so directly at the hearing.
The dual growth factor mechanism
Semax drives multidirectional expression of both NGF and BDNF genes. BDNF is essential for neuron survival, the growth of new neurons and synapses, and neuroplasticity. Few single compounds engage both pathways at once, and that is the mechanistic core of the case for it.
What the Research Shows
| Line of evidence | Design | Reported finding |
|---|---|---|
| Stroke recovery (Gusev, Martynov et al., 2018) | n=110, non-randomised, not placebo-controlled | Plasma BDNF rose; Barthel Index and MRC motor scale improved over ~5 months on 6,000mcg/day intranasal |
| Cognition in healthy fatigued adults | Controlled, single dose 16mcg/kg | 71% memory-test accuracy vs 41% control, reported to persist up to 24 hours |
| Alzheimer’s model (2025) | Transgenic mice, 3 behavioural tests | Improved cognition; reduced amyloid plaque inclusions in cortex and hippocampus |
| Spinal cord injury (2025, Br J Pharmacol) | Mouse model | Functional recovery via Oprm1; reduced neuroinflammation and oxidative cell death |
The stroke data is real human outcome data rather than an extrapolation from animals, which matters. It is also neither randomised nor placebo-controlled, and effect sizes were not reported in the published abstract — real limits on how strongly it can be read.
What FDA Said at the Hearing
FDA countered that much of the supporting literature is published in Russian and frequently omits the routes of administration, dosing, and study detail needed to verify the reported outcomes. Acting PCAC chair Brian Serumaga also flagged a health-literacy risk: Semax is easily confused with semaxanib, an entirely different compound.
It passed 8-5 with one abstention, the second-strongest margin of the meeting.
The bottom line
An unusual profile: long-running real-world clinical use in one country paired with an active and growing preclinical base, but no Western randomised controlled trial. Among the compounds on the July 2026 docket, Semax has the strongest human track record — which is a statement about the others as much as about Semax.
Also in the Range
Also available paired with Selank, which is the more common way it is run — Selank offsets the intensity Semax can produce.